Estudo físico-químico da atividade fungicida de derivados anfifílicos de quitosana contra fungos do gênero Aspergillus : interação com modelos de membranas

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Desenvolvimento de filmes biodegradáveis à base de zeína, caracterização das propriedades funcionais e estruturais e avaliação do uso como cobertura na conservação das características físico-químicas do queijo Minas padrão

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Caracterização Físico-Química de Polpas de Frutas do Bioma Amazônia

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Influência da incorporação de nanopartículas de trimeta- fosfato de sódio associado ou não à clorexidina nas proprie- dades microbiológicas, físico-mecânicas e de redução da desmineralização de cimento de ionômero de vidro

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Caracterização térmica e físico-química do sistema argila-8-hidroxiquinolina na remoção de íons Fe(III), Ni(II) e Co(II)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Avaliação dos parâmetros físico-químicos e estabilidade de compostos bioativos em óleos de polpa e amêndoa de frutos amazônicos

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Análise isotópica, físico-química, centesimal e energética de água de coco

Pós-graduação em Agronomia (Energia na Agricultura) - FCA

Variabilidade da frequência cardíaca e a dinâmica miocárdica em cães com degeneração mixomatosa da valva mitral submetidos a um programa de condicionamento físico

Pós-graduação em Medicina Veterinária - FCAV

Exercício físico resistido em pacientes com doença renal crônica em hemodiálise: ensaio clínico randomizado controlado

Pós-graduação em Fisioterapia - FCT

Mapeamento físico de sequênias repetitivas de DNA no genoma de espécies do gênero Trichomycterus (Siluriformes, Trichomycteridae)

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)

Biomarcadores cardíacos em cães com degeneração mixomatosa da valva mitral submetidos a um programa de condicionamento físico

Pós-graduação em Medicina Veterinária - FCAV

Efeitos preventivos do treinamento físico na expressão das proteínas Cox-2 e Vegf de ratos tratados com dexametasona

Dexamethasone is a synthetic glucocorticoid widely used to treat allergic and inflammatory processes. This drug is used in three main situations, are used to contain acute or chronic inflammatory processes, or like immunosuppressive drug's. In these cases the patient will receive high doses for a chronic period and, therefore, has a much greater chance of adverse side effects, such as hypertension, diabetes and dyslipidemia. Dexamethasone promotes deleterious effects on the arachidonic acid pathway, when administered in high doses, because it is a potent anti-inflammatory drug. We recently demonstrated that dexamethasone significantly reduces the protein expression of vascular endothelial growth factor (VEGF) in both skeletal muscle and heart, but the mechanisms involved remain unclear. Meanwhile, exercise has been shown to be effective against high blood pressure, diabetes and dyslipidemia, promoting, among other factors, the increase in VEGF and angiogenesis. One possible explanation for these effects would be the creation of new vessels mediated by inflammation, or by the stimulation of the formation of products of the metabolism of arachidonic acid (AA), such as prostaglandin E2 (PGE2) and VEGF, by increasing the stimulation of the enzymes cyclooxygenase 1 and 2 (COX-1 and COX-2). Little is known about the preventive effects of training on the action of dexamethasone in the arachidonic acid pathway. Therefore, the aim of this study was to determine whether aerobic exercise training, performed before and concomitant treatment with dexamethasone, was able to prevent the effects of the dexamethasone in the protein expression of COX-2 and VEGF. For this, we used young Wistar rats (n = 40) which were randomly divided into 4 groups: sedentary control (SC), sedentary and treated with dexamethasone (SD), trained control (TC) and trained and treated with dexamethasone (TD). These rats performed aerobic exercise training, 60% of maximum capacity, 5

Presença de fatores de risco dependentes ou não de esforço físico em praticantes de corrida de rua

In order to reduce the sedentarism and to improve population's health condition, many physical activity incentive programs have been stimulated. As a result, many people have adhered to street racing, but their health condition is almost always ignored. The aim of this study was to evaluate street racers' health condition, identifying the presence of cardiovascular risk factors as well as problems associated to street racing. The study case was composed by 111 racers from the town of Bauru (94 men and 17 women) aged in average 39±13 years old, who were evaluated in 4 street race competitions. The subjects answered to an anamnesis with questions about their socioeconomic status, medicine use, cardiovascular risk, physical exercise practices, and issues related to racing and injury. Weight (kg) and height (m) were measured to calculate the body mass index (BMI, kg/m²) as well as systolic and diastolic blood pressure (BP), heart rate (HR), abdominal circumference (AC), and flexibility. It could be observed that the majority of racers were Caucasian, married and belonged to social classes over C. The prevalent age was between 18 and 35 years old (42%). Among the participants, 38.7% have already undergone some kind of surgery and 13% declared having some health problem. The questionnaire pointed out that 36% had low and moderate cardiovascular risk. It could be noticed from the AC that 10% of men and 18% of women had high cardiac risk. Among the tested, 43.2% (24.3% altered and 18.9% borderline) showed high BP on the day of the test, but only 2.7% had self-declared hypertensive. In relation to injury, 36% had already had lesions of some kind, 27.5% of which had occurred in the last 8 months. 66.6% had derived from training or racing competitions and the knee was the mostly affected body part. Only 43% had professional orientation by a physical education teacher during their training and the main reasons for them to begin racing practice were...

Efeitos preventivos do exercício físico sobre as proteínas ciclooxigenase-2 (COX-2) e fator de crescimento de vasos derivado do endotélio (VEGF) no músculo cardíaco em ratos tratados com dexametasona

Dexamethasone (DEXA) is a synthetic glucocorticoid widely used in the handling of several drugs, for its proven benefits in fighting inflammation and allergies. Despite their benefits, their chronic use leads to several side effects that include changes in the body in the metabolism of carbohydrates, lipids and proteins. Moreover, being an anti-inflammatory, acts on the arachidonic acid pathway, reducing the expression of the enzyme cyclooxygenase (COX-2) and growth factor derived from the endothelium of blood vessels (VEGF) in various tissues. However, its effects on the myocardium are still uncertain. The physical training (PT), in turn, promotes effects contrary to those caused by chronic use of DEXA, however, little is known about the preventive effects of TF in the side effects of Dexa in the myocardium. Therefore, the aim of this study was to determine if the TF has the ability to prevent and/or mitigate the effects of Dexa in protein expression of COX-2 and VEGF in the myocardium. Forty animals were divided into 4 groups: sedentary control (SC), sedentary treated with Dexa (SD), trained control (TC) and Trained treated with Dexa (TD) and submitted to a protocol of physical training on the treadmill for 70 days (1 h/day-5 days per week, 60% of physical capacity) or kept sedentary. Over the past 10 days, rats were treated with Dexa (Decadron, 0.5 mg/kg per day, ip) or saline. During training the animals were weighed weekly and during treatment daily. At the end of treatment was made to measure fasting glucose levels of animals. The rats were killed with excess anesthesia and cardiac muscle was removed, weighed, homogenized, centrifuged and stored at -20° C for analysis of protein expression of VEGF and COX-2 by Western blotting technique. Treatment with dexamethasone caused a weight loss of 18% in sedentary animals and 13% in trained as well as elevated levels of fasting glucose in sedentary (88%). The TF was unable to mitigate the loss in...

Efeitos preventivos do exercício físico na expressão da miostatina em ratos tratados com Dexametasona

Muscle atrophy is always associated with Dexamethasone (Dexa) treatment, however the mechanisms are not completely understood. This study investigated the effects of Dexa on myostatin and p70S6K protein expression and if previous exercise training (T) can attenuate these effects. Eighty rats were distributed into 4 groups: sedentary control (SC), sedentary treated with Dexa (SD; 0,5 mg/kg per day, i.p., 10 days), trained control (TC) and trained treated with Dexa (TD) and underwent a training period where they were either submitted to a running protocol (60% of physical capacity, 5 days/week for 8 weeks) or kept sedentary. After T period, animals underwent Dexa treatment concomitant with training. Western Blot was performed to identify myostatin and p70S6k protein expression in the tibialis anterior (TA) and soleus (SOL) muscle. Ten days of Dexa treatment increased fasting glucose (SD=+62%), however previous T attenuated this increase (TD=+20%, p<0.05). Dexa determined significant decrease in body weight in TD (-22%) and SD (-25%), followed by TA weight reduction in SD (-23%) and TD (-20%). Previous training could not avoid these decreases. Myostatin protein expression was not altered by dexa treatment or training in TA muscle but in SOL muscle it was significantly modified after T, regardless of treatment (TC=+%23 and TD=+25) compared with their respective controls. The protein p70S6K was not modified neither by dexa nor training in any of the analyzed muscle or condition. The results of this study allowed us to conclude that previous training attenuates the hyperglycemia induced by Dexa, however it did not prevent the body or muscle weight reductions. Even in the presence of muscle atrophy, the expression of myostatin and p70S6K do not justify the mechanisms of muscle loss induced by Dexa, which suggests that other catabolic or anabolic proteins could be involved in the process of muscle atrophy after 10 days of treatment with Dexa